Brokers Set Expectations for CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities researchers at Lifesci Capital issued their Q1 2025 EPS estimates for Perspective Therapeutics in a report issued on Thursday, March 27th. Lifesci Capital analyst D. Kennedy forecasts that the company will earn ($0.28) per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Perspective Therapeutics' Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.10) EPS.

A number of other research firms have also issued reports on CATX. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Monday. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $14.44.

Perspective Therapeutics Stock Down 4.4 %

Shares of NYSE:CATX traded down $0.09 during mid-day trading on Monday, hitting $1.96. The stock had a trading volume of 1,182,906 shares, compared to its average volume of 1,007,418. The company's 50 day moving average is $2.82 and its 200-day moving average is $6.04. Perspective Therapeutics has a 12-month low of $1.90 and a 12-month high of $19.05.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CATX. Y Intercept Hong Kong Ltd acquired a new position in Perspective Therapeutics in the 4th quarter valued at $33,000. Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at about $137,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the fourth quarter worth about $34,000. National Bank of Canada FI lifted its position in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $152,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Juan Graham purchased 33,333 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was bought at an average price of $2.25 per share, with a total value of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the purchase, the director now owns 108,982 shares in the company, valued at $233,221.48. This represents a 53.85 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 115,696 shares of company stock valued at $256,344 over the last ninety days. Corporate insiders own 3.52% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.